Guardant Health, Inc. (NASDAQ:GH - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $42.00 and last traded at $42.12, with a volume of 650168 shares traded. The stock had previously closed at $36.66.
GH has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their price target on shares of Guardant Health from $48.00 to $50.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Leerink Partners decreased their target price on shares of Guardant Health from $60.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, October 17th. Sanford C. Bernstein cut their price target on Guardant Health from $40.00 to $35.00 and set an "outperform" rating on the stock in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group boosted their price objective on Guardant Health from $32.00 to $36.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Fifteen research analysts have rated the stock with a buy rating, According to MarketBeat.com, Guardant Health has an average rating of "Buy" and an average target price of $40.60.
Read Our Latest Stock Analysis on GH
The firm has a market capitalization of $5.21 billion, a PE ratio of -9.97 and a beta of 1.28. The business's 50-day moving average price is $33.91 and its 200-day moving average price is $29.02.
Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.33). The company had revenue of $191.48 million during the quarter, compared to analyst estimates of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company's revenue was up 33.9% compared to the same quarter last year. During the same period last year, the company posted ($0.73) earnings per share. On average, analysts anticipate that Guardant Health, Inc. will post -3.44 EPS for the current fiscal year.
In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the transaction, the director now owns 2,676 shares in the company, valued at $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Meghan V. Joyce sold 2,896 shares of the business's stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares of the company's stock, valued at $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,432 shares of company stock worth $175,423. 5.50% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the business. Lord Abbett & CO. LLC acquired a new stake in Guardant Health during the third quarter worth about $15,624,000. Cerity Partners LLC lifted its position in shares of Guardant Health by 54.6% in the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company's stock worth $4,473,000 after acquiring an additional 68,883 shares during the period. Geode Capital Management LLC grew its holdings in shares of Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock worth $64,754,000 after purchasing an additional 29,686 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Guardant Health by 1,282.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company's stock valued at $28,128,000 after purchasing an additional 1,137,482 shares during the period. Finally, First Light Asset Management LLC raised its stake in shares of Guardant Health by 119.7% in the second quarter. First Light Asset Management LLC now owns 416,967 shares of the company's stock valued at $12,042,000 after purchasing an additional 227,202 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.